Türkiye-based Initio Cell is taking a significant step towards advancing drug development and diagnostics on a global scale. Their expansion includes a brand-new lab at the Leiden Bio Science Park in the Netherlands, dedicated to growing R&D and contract research organization (CRO) services focused on their cutting-edge organ-on-chip devices.
Initio Cell’s commitment to making a difference in world health by developing patented, multi-functional organ-on-a-chip devices and tests for drug discovery is truly remarkable. The Netherlands’ vibrant life sciences ecosystem, thriving academic collaboration, and strong government support make it the perfect base for such groundbreaking innovation.
Aydın Öztunali, CEO and co-founder of Initio Cell, shared his excitement: “We visited various science parks in different countries, and the Leiden Bio Science Park was by far the best. The infrastructure and close collaboration with academia were present, all companies were in compatible life science fields, and maybe the most important was the people factor. The Leiden Bio Science Park administration is there to help us grow with a sincerely friendly and resourceful attitude.”
The Netherlands: driving force in medical progress and patient outcomes
The Dutch “quadruple helix” approach, connecting the private sector, government, academia, and patients, creates an ideal environment for innovation in R&D. Initio Cell’s pioneering organ-on-chip technology has the potential to revolutionize drug discovery by mimicking in-vivo conditions, advancing precision medicine, and creating microenvironments resembling various tissues.
Cutting-edge diagnostics and treatment
In the realm of diagnostic and treatment advancements, the Netherlands has solidified its prominent status as a frontrunner in life sciences & health, and research and development. Guided by robust public-private collaborations, exemplified by notable partnerships like the Institute for Human Organ and Disease Model Technologies (hDMT) and Regenerative Medicine Crossing Borders (RegmedXB), the Netherlands stands at the forefront of innovation in the Organs-on-a-Chip field. Recent substantial investments from the National Growth Fund and Dutch Research Council (NWO) are serving as catalysts, propelling the trajectory of developments such as the Organs-on-a-Chip pilot line, NXTgen High Tech, and the Organ-on-Chip Development Center towards even greater heights.
Navigating Success Together
Initio Cell’s journey to the Netherlands was supported by the NFIA Istanbul office and the regional economic development agency InnovationQuarter. Both are part of the Invest in Holland network, providing insightful information, facilitating fact-finding trips, and ensuring a smooth transition.
Stay tuned for more updates on this exciting collaboration between Initio Cell and the Dutch life sciences ecosystem, as we collectively work towards transforming drug development and diagnostics worldwide.
Get in touch with us!